Clinical trial
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism…
NCT00037518 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00037518 |
|---|---|
| Title | A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer |
| Official title | An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hyperparathyroidism, Parathyroid Neoplasms |
| Intervention type | Drug |
| Interventions | AMG 073 |
| Enrollment | 46 |
| Start date | Apr 1, 2001 |
| First posted | May 20, 2002 |
| Last update posted | May 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: